Pharmacology of Antiviral Drugs

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1139

Special Issue Editor


E-Mail Website
Guest Editor
TrippBio, Inc., Jacksonville, FL 32256, USA
Interests: antiviral, influenza virus; repurposed; respiratory syncytial virus (rsv); respiratory virus; rsv; SARS-CoV-2; therapeutic

Special Issue Information

Dear Colleagues,

Viral infections cause significant morbidity and mortality across the globe in both humans and animals. As the world emerges from the latest viral pandemic, it is clear that considerable work remains to identify and characterize new antiviral treatments. We therefore invite submissions for our upcoming Special Issue on the pharmacology of antiviral drugs. This issue aims to explore and elucidate the intricate pharmacological aspects of antiviral medications. Researchers and experts are encouraged to contribute original research articles, reviews, and short communications that delve into various aspects of antiviral pharmacology. We welcome submissions that cover a wide range of topics, including, but not limited to, molecular interactions between drugs and viral targets, pharmacokinetics, pharmacodynamics, and the influence of host factors on drug efficacy. Additionally, we seek contributions addressing emerging topics such as drug resistance, novel drug delivery approaches, and advancements in medicinal chemistry to optimize antiviral treatment strategies in humans and animals.

Join us in advancing our understanding of antiviral pharmacology and shaping the future of antiviral therapy. Submit your contributions to this Special Issue to contribute to the global effort in combating viral infections and improving public health outcomes.

Dr. David E. Martin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacology
  • clinical pharmacology
  • antiviral therapy
  • antiviral prophylaxis
  • human viruses
  • animal viruses
  • pharmacokinetics
  • pharmacodynamics
  • drug resistance.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 586 KiB  
Article
Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients
by Nadia Exquis, Benjamin Dionisi, Caroline Flora Samer, Victoria Rollason, François Curtin, Dina Zekry, Christophe Graf, Virgnie Prendki and Kuntheavy Ing Lorenzini
Viruses 2024, 16(6), 864; https://doi.org/10.3390/v16060864 - 28 May 2024
Viewed by 657
Abstract
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs. (2) Methods: A retrospective study of electronic health records (EHRs) aiming to describe antiviral (nirmatrelvir and ritonavir (nirmatrelvir/r) or remdesivir) use, drug–drug [...] Read more.
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs. (2) Methods: A retrospective study of electronic health records (EHRs) aiming to describe antiviral (nirmatrelvir and ritonavir (nirmatrelvir/r) or remdesivir) use, drug–drug interactions (DDIs) and adverse drug reactions (ADRs) in elderly patients (75 and over), hospitalized with mild-to-moderate COVID-19 between July 2022 and June 2023. (3) Results: Out of 491 patients (mean age: 86.9 years), 180 (36.7%) received nirmatrelvir/r, 78 (15.9%) received remdesivir, and 233 (47.4%) received no antiviral therapy. No association was found between the choice of antiviral and the demographic or medical data. No serious ADR was observed. Nirmatrelvir/r dosage adjustment was inadequate in 65% of patients with renal impairment. In total, 128 patients (71%) on nirmatrelvir/r had potential pharmacokinetic DDIs, with 43 resulting in a possibly related ADR. In the remdesivir group, pharmacodynamic DDIs were more frequent, with QTc prolongation risk in 56 patients (72%). Only 20 patients underwent follow-up ECG, revealing QTc prolongation in 4. (4) Conclusions: There is an underutilization of antivirals despite their justified indications. Nirmatrelvir/r dosage was rarely adjusted to renal function. Dose adjustments and closer monitoring are needed due to the high risk of drug interactions. Full article
(This article belongs to the Special Issue Pharmacology of Antiviral Drugs)
Show Figures

Figure 1

Back to TopTop